Data / Research funding / Cooley's Anemia
Cooley's Anemia: 45 NIH awards ($47.9M) to 28 organizations
45 NIH awards ($47.9M) in the NIH spending category Cooley's Anemia, to 28 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
45 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Development of a Clinical Hemoglobin Modulator | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $3,473,811 | June 1, 2020 | May 31, 2024 | PERRINE, SUSAN PARK | reporter.nih.gov |
| Regulation of Hemoglobin Switching | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,354,270 | August 5, 2013 | January 31, 2027 | BLOBEL, GERD A | reporter.nih.gov |
| Affordable, quantitative, point-of-care microchip-electrophoresis for screening and treatment monitoring of sickle cell disease, thalassemias, and anemias | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,986,386 | September 1, 2018 | February 28, 2026 | GALEN, PETER | reporter.nih.gov |
| Developing gene therapy strategies to treat alpha thalassemia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,821,947 | January 1, 2022 | December 31, 2025 | MACKENZIE, TIPPI | reporter.nih.gov |
| The Role of Erythroferrone in Regulating Bone Metabolism in Beta-Thalassemia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,707,032 | September 1, 2015 | January 31, 2026 | GINZBURG, YELENA | reporter.nih.gov |
| In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia and Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,618,613 | June 1, 2016 | July 31, 2025 | LIEBER, ANDRE MICHAEL | reporter.nih.gov |
| ULK-mediated autophagy of α-globin in ß-thalassemia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,597,287 | July 1, 2022 | June 30, 2027 | WEISS, MITCHELL J | reporter.nih.gov |
| Chemotherapy-free cure of hemoglobin disorders through base editing | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,334,252 | September 1, 2023 | May 31, 2027 | BAUER, DANIEL EVAN | reporter.nih.gov |
| Multiplex base/prime editors for in vivo selection of modified HSPCs in hemoglobinopathy | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,218,334 | January 17, 2017 | December 31, 2025 | KIEM, HANS-PETER | reporter.nih.gov |
| MECHANISM OF ACTION OF ERYTHROFERRONE AND PATHOLOGICAL IMPLICATIONS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,105,574 | September 20, 2020 | June 30, 2025 | GANZ, TOMAS | reporter.nih.gov |
| Targeting ZNF410 for HbF reactivation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,023,010 | March 1, 2023 | February 28, 2027 | BAUER, DANIEL EVAN | reporter.nih.gov |
| Development and validation of novel mouse models and expression vectors for characterizing severe alpha-thalassemia pathophysiology and evaluating gene therapy approaches. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,927,121 | June 1, 2023 | May 31, 2027 | RIVELLA, STEFANO | reporter.nih.gov |
| The dissection of non-canonical cis-regulatory elements downstream of beta-globin locus in the fetal hemoglobin gene regulation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,372,419 | September 1, 2023 | July 31, 2028 | ZHANG, XIAOTIAN | reporter.nih.gov |
| Pathological consequences of iron excess and hypoxia in β-thalassemia pregnancy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,307,517 | September 20, 2024 | July 31, 2029 | COLLINS, JAMES F. | reporter.nih.gov |
| Investigating PUM1 mediated post-transcriptional regulation of human hemoglobin switching and erythropoiesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,242,739 | April 1, 2023 | March 31, 2028 | GNANAPRAGASAM, MERLIN NITHYA | reporter.nih.gov |
| DEGRADATION OF BCL11A PROTEIN FOR HbF REACTIVATION | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,149,236 | August 7, 2023 | July 31, 2028 | ORKIN, STUART H | reporter.nih.gov |
| Targeting PGC-1a for the treatment of sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,050,000 | July 1, 2022 | May 31, 2026 | CUI, SHUAIYING | reporter.nih.gov |
| Therapeutic BCL11A enhancer gene editing to induce fetal hemoglobin in β-hemoglobinopathy patients | NIH | National Heart, Lung, and Blood Institute | 2021 | $886,788 | June 18, 2020 | November 30, 2022 | BAUER, DANIEL EVAN | reporter.nih.gov |
| Molecular Analysis of Normal and Thalassemic DNA | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $885,000 | April 1, 1982 | April 30, 2024 | ORKIN, STUART H | reporter.nih.gov |
| Multiplex base/prime editors for in vivo selection of modified HSPCs in hemoglobinopathy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $810,459 | January 17, 2017 | March 31, 2022 | KIEM, HANS-PETER | reporter.nih.gov |
| PNA Nanoparticles for Gene Editing In Vivo | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $808,473 | July 5, 2019 | June 30, 2023 | GLAZER, PETER M | reporter.nih.gov |
| Chemical tools for modulating the fetal hemoglobin inducer BCL11A | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $772,000 | July 1, 2024 | April 30, 2028 | DASSAMA, LAURA | reporter.nih.gov |
| Targeted protein degraders for the treatment of b-hemoglobinopathies | NIH | National Heart, Lung, and Blood Institute | 2025 | $765,622 | January 1, 2025 | November 30, 2028 | CREWS, CRAIG M | reporter.nih.gov |
| Zip Proteins and Iron Metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $764,054 | September 17, 2009 | April 30, 2024 | KNUTSON, MITCHELL D | reporter.nih.gov |
| MODELING MRI-BASED TISSUE RELAXATION IN THE PRESENCE OF IRON OVERLOAD AND STEATOSIS | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $589,413 | May 1, 2021 | February 28, 2025 | TIPIRNENI-SAJJA, AARYANI | reporter.nih.gov |
| Nanochelation Therapies for Iron Overload Disorders | NIH | National Heart, Lung, and Blood Institute | 2021 | $543,043 | January 1, 2021 | August 31, 2023 | KIM, JONGHAN | reporter.nih.gov |
| Activin signaling in normal and disordered erythropoiesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $521,104 | September 30, 2010 | January 31, 2023 | RIVELLA, STEFANO | reporter.nih.gov |
| Defining the mechanisms of hemoglobin switching and genotoxicities associated with its manipulation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $443,456 | April 1, 2022 | August 19, 2024 | DOERFLER, PHILLIP A | reporter.nih.gov |
| In vivo gene editing of hematopoietic stem and progenitor cells | NIH | National Heart, Lung, and Blood Institute | 2021 | $417,500 | March 1, 2018 | February 29, 2024 | WAGERS, AMY JO | reporter.nih.gov |
| Homologous Recombination Mediated Gene Correction for the Hemoglobinopathies | NIH | National Heart, Lung, and Blood Institute | 2021 | $395,344 | August 1, 2018 | June 30, 2022 | PORTEUS, MATTHEW H | reporter.nih.gov |
| A Rapid and Inexpensive Point-of-Care Test for Beta-Thalassemia Carriers | NIH | National Heart, Lung, and Blood Institute | 2021 | $345,189 | August 15, 2020 | July 31, 2022 | GEISBERG, MARK | reporter.nih.gov |
| Iron Catalyzed H2S and its Prevalence in Hemolytic and Iron Overload Disorders | NIH | National Heart, Lung, and Blood Institute | 2021 | $322,000 | July 1, 2019 | June 30, 2024 | HINE, CHRISTOPHER MICHAEL | reporter.nih.gov |
| In vivo Sickle Cell Disease Gene Therapy Using a Novel Virus Like Particle | NIH | National Heart, Lung, and Blood Institute | 2024 | $300,000 | September 10, 2024 | September 9, 2025 | JOHNSON, DAVID SCOTT | reporter.nih.gov |
| ZIP Proteins and Iron Metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 | $225,000 | September 17, 2009 | August 31, 2025 | KNUTSON, MITCHELL D | reporter.nih.gov |
| Defining the mechanisms of hemoglobin switching and genotoxicities associated with its manipulation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $158,220 | September 21, 2024 | December 31, 2026 | DOERFLER, PHILLIP A | reporter.nih.gov |
| Development of novel fetal hemoglobin inducers using targeted protein degradation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $120,746 | April 16, 2023 | April 15, 2026 | ZHENG, SIJIN | reporter.nih.gov |
| Mechanisms of Heme and Non-heme Iron Absorption in Murine Models of Iron Overload | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 | $100,000 | September 25, 2022 | December 31, 2023 | COLLINS, JAMES F. | reporter.nih.gov |
| Iron Pathobiology in β-thalassemia Pregnancy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 | $100,000 | September 21, 2023 | August 31, 2024 | COLLINS, JAMES F. | reporter.nih.gov |
| Roles of BCL11A in γ-globin repression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $90,000 | March 1, 2020 | February 28, 2022 | LIU, NAN | reporter.nih.gov |
| Reactivation of Gamma Globin Expression in β-Hemoglobinopathies | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $79,166 | September 1, 2022 | August 31, 2024 | BALBIN-CUESTA, GINETTE THERESA | reporter.nih.gov |
| Investigating the mechanisms of polycomb group protein mediated fetal hemoglobin silencing | NIH | National Heart, Lung, and Blood Institute | 2025 | $54,538 | September 4, 2025 | September 3, 2029 | KAMINSKI, PAUL | reporter.nih.gov |
| High-resolution functional mapping of non-coding sequences regulating fetal hemoglobin | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $37,547 | March 1, 2025 | February 28, 2026 | BECERRA, BASHEER | reporter.nih.gov |
| Post-Transcriptional Regulatory Mechanisms of Fetal Hemoglobin Repression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $33,743 | December 1, 2019 | November 30, 2021 | COYNE, STEVEN | reporter.nih.gov |
| Eleventh Cooley's Anemia Symposium | NIH | National Heart, Lung, and Blood Institute | 2022 | $10,000 | September 1, 2022 | August 31, 2023 | KWIATKOWSKI, JANET L | reporter.nih.gov |
| Hemoglobin Switching Meeting | NIH | National Heart, Lung, and Blood Institute | 2025 | $10,000 | November 9, 2024 | October 31, 2025 | SANKARAN, VIJAY GANESH | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Boston Children's Hospital | Boston, MA | 7 | $7.4 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 3 | $5.8 million | 0 | $0 |
| Phoenicia Biosciences, Inc. | Weston, MA | 1 | $3.5 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 2 | $3 million | 0 | $0 |
| Hemex Health, Inc. | Portland, OR | 1 | $3 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 1 | $2.8 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 1 | $2.7 million | 0 | $0 |
| University of Washington | Seattle, WA | 1 | $2.6 million | 0 | $0 |
| University of Florida | Gainesville, FL | 5 | $2.5 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 1 | $2.2 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 1 | $2.1 million | 0 | $0 |
| Yale University | New Haven, CT | 3 | $1.7 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 1 | $1.4 million | 0 | $0 |
| Cleveland State University | Cleveland, OH | 1 | $1.2 million | 0 | $0 |
| Stanford University | Stanford, CA | 2 | $1.2 million | 0 | $0 |
| Boston Medical Center | Boston, MA | 1 | $1.1 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 1 | $810,459 | 0 | $0 |
| University of Memphis | Memphis, TN | 1 | $589,413 | 0 | $0 |
| University of Massachusetts Lowell | Lowell, MA | 1 | $543,043 | 0 | $0 |
| Joslin Diabetes Center | Boston, MA | 1 | $417,500 | 0 | $0 |
| Silver Lake Research Corporation | Azusa, CA | 1 | $345,189 | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 1 | $322,000 | 0 | $0 |
| Gigamune, Inc. | San Francisco, CA | 1 | $300,000 | 0 | $0 |
| Versiti Blood Health, Inc. | Milwaukee, WI | 1 | $158,220 | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 1 | $79,166 | 0 | $0 |
| Harvard Medical School | Boston, MA | 2 | $71,290 | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 1 | $54,538 | 0 | $0 |
| New York Academy of Sciences | New York, NY | 1 | $10,000 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 19 | $9,010,780 | 0 | $0 |
| 2024 | 21 | $10,815,439 | 0 | $0 |
| 2023 | 19 | $10,048,527 | 0 | $0 |
| 2022 | 18 | $8,424,368 | 0 | $0 |
| 2021 | 18 | $9,578,839 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 1 award here | |
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | 93.839 | December 3, 2026 | Not listed | Same assistance listing 93.839 as 27 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | 93.839 | December 3, 2026 | Not listed | Same assistance listing 93.839 as 27 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.839 | December 4, 2026 | Not listed | Same assistance listing 93.839 as 27 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional) | PAR-27-039 | NIH | 93.839 | January 5, 2027 | Not listed | Same assistance listing 93.839 as 27 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional) | PAR-27-040 | NIH | 93.839 | January 5, 2027 | Not listed | Same assistance listing 93.839 as 27 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.839 | January 7, 2027 | $375,000 | Same assistance listing 93.839 as 27 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.839 | January 7, 2027 | Not listed | Same assistance listing 93.839 as 27 awards here |
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required) | PAR-25-025 | NIH | 93.839 | February 3, 2027 | $1.5 million | Same assistance listing 93.839 as 27 awards here |
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required) | PAR-25-026 | NIH | 93.839 | February 3, 2027 | Not listed | Same assistance listing 93.839 as 27 awards here |
| Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) | PAR-27-125 | NIH | 93.839 | February 16, 2027 | Not listed | Same assistance listing 93.839 as 27 awards here |
| Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed) | RFA-DK-27-108 | NIH | 93.839 | March 10, 2027 | $500,000 | Same assistance listing 93.839 as 27 awards here |
| NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) | PAR-25-032 | NIH | 93.839 | March 16, 2027 | Not listed | Same assistance listing 93.839 as 27 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.839 | April 5, 2027 | Not listed | Same assistance listing 93.839 as 27 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.839 | April 5, 2027 | Not listed | Same assistance listing 93.839 as 27 awards here |
| Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Clinical Trials Not Allowed) | RFA-OD-25-003 | NIH | 93.839 | April 9, 2027 | $200,000 | Same assistance listing 93.839 as 27 awards here |
| NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional) | RFA-HL-26-002 | NIH | 93.839 | April 28, 2027 | Not listed | Same assistance listing 93.839 as 27 awards here |
| NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional) | RFA-HL-26-003 | NIH | 93.839 | April 28, 2027 | Not listed | Same assistance listing 93.839 as 27 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required) | PA-24-175 | NIH | 93.839 | May 7, 2027 | Not listed | Same assistance listing 93.839 as 27 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.839 | May 7, 2027 | Not listed | Same assistance listing 93.839 as 27 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.